Solid Biosciences (SLDB) Given a $6.00 Price Target by Citigroup Analysts

Solid Biosciences (NASDAQ:SLDB) has been assigned a $6.00 price objective by stock analysts at Citigroup in a research note issued on Thursday, TipRanks reports. The brokerage currently has a “hold” rating on the stock. Citigroup‘s price objective indicates a potential downside of 0.66% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the stock. Chardan Capital reissued a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Thursday, February 7th. Svb Leerink cut shares of Solid Biosciences from an “outperform” rating to a “market perform” rating in a report on Friday, February 8th. Leerink Swann cut shares of Solid Biosciences from an “outperform” rating to a “market perform” rating in a report on Thursday, February 7th. ValuEngine raised shares of Solid Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday, March 19th. Finally, Zacks Investment Research raised shares of Solid Biosciences from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a report on Wednesday, February 13th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company’s stock. Solid Biosciences currently has an average rating of “Hold” and an average price target of $19.82.

NASDAQ SLDB traded down $0.14 during trading hours on Thursday, reaching $6.04. The company’s stock had a trading volume of 330,214 shares, compared to its average volume of 871,348. The company has a quick ratio of 10.31, a current ratio of 6.99 and a debt-to-equity ratio of 0.07. Solid Biosciences has a 52 week low of $5.23 and a 52 week high of $54.84. The stock has a market capitalization of $209.25 million, a P/E ratio of -2.68 and a beta of 1.68.

Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Monday, May 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.22). As a group, equities research analysts expect that Solid Biosciences will post -2.53 earnings per share for the current year.

In other Solid Biosciences news, Director Juan Andrey Zarur sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $10.00, for a total value of $80,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Boxer Capital, Llc sold 450,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $9.88, for a total transaction of $4,446,000.00. The disclosure for this sale can be found here. 31.20% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the business. BlueMountain Capital Management LLC bought a new position in shares of Solid Biosciences during the 1st quarter worth about $379,000. Morgan Stanley increased its holdings in shares of Solid Biosciences by 142.4% during the 1st quarter. Morgan Stanley now owns 54,389 shares of the company’s stock worth $501,000 after purchasing an additional 31,948 shares during the period. Marshall Wace LLP boosted its position in shares of Solid Biosciences by 226.2% during the 1st quarter. Marshall Wace LLP now owns 69,813 shares of the company’s stock valued at $642,000 after acquiring an additional 48,409 shares in the last quarter. Caption Management LLC acquired a new stake in shares of Solid Biosciences during the 1st quarter valued at about $354,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Solid Biosciences during the 1st quarter valued at about $887,000. Institutional investors own 63.39% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Featured Story: Terms to Better Understand Call Options

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.